Mobile version

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

08 September 2008

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

The Reimbursement Committee's first recommendation of 29 January 2008 is available via the factbox to the right. It contains a list of links to the references that the Reimbursement Committee emphasised in its recommendation. The recommendation was submitted for consultation with a consultation deadline on 5 May 2008 , and the consultation responses have been presented to the Reimbursement Committee. The published consultation responses can be found in the factbox (in Danish only).

The additional recommendation of 2 September 2008 is now submitted for consultation.

Based on the consultation responses, the Reimbursement Committee has drawn up an additional recommendation. There is a link to the additional recommendation of 2 September 2008 in the factbox to the right.

On 4 September, the Danish Medicines Agency has initiated a consultation of the companies whose medicinal products are comprised by the Committee's recommendations. In the factbox to the right, you can see the Danish Medicines Agency's consultation letter of 4 September 2008 and a list of the medicinal products marketed in the period 13 January 2008 to 25 August 2008 , which are comprised by the Reimbursement Committee's recommendations. The consultation deadline is Friday 19 September 2008.

Relevant stakeholders have been informed

A notification about the Reimbursement Committee's additional recommendation has also been sent to the relevant Danish scientific societies and patient organisations, along with the National Board of Health and the Institute for Rational Pharmacotherapy.

For further information, please contact the Reimbursement Section: Send an email.

Danish Medicines Agency, 9 September 2008